Ahmed H Al-Jedai
Overview
Explore the profile of Ahmed H Al-Jedai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
103
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheerah H, Al-Jedai A, Al-Jerian N, Al-Otaiby M, Al-Seraihi A, Al-Huzami S, et al.
Vaccine
. 2025 Feb;
52:126937.
PMID: 40014982
Background: The simultaneous spread of COVID-19 and seasonal influenza is an evolving healthcare challenge. This study examines the clinical characteristics of influenza and COVID-19 patients in Saudi Arabia and evaluates...
2.
Saadah O, AlAmeel T, Al Sarkhy A, Hasosah M, Al-Hussaini A, Almadi M, et al.
Saudi J Gastroenterol
. 2024 Aug;
PMID: 39215473
The management of inflammatory bowel disease (IBD) in children and adolescents is challenging. Clear evidence-based guidelines are required for this population. This article provides recommendations for managing IBD in Saudi...
3.
Al-Jedai A, Almudaiheem H, Al-Homood I, Almaghlouth I, Bahlas S, Alolaiw A, et al.
Curr Rheumatol Rev
. 2024 May;
PMID: 38693734
Objective: To provide evidence-based clinical practice recommendations for managing Systemic Lupus Erythematosus (SLE) in Saudi Arabia. Methods: This EULAR-adapted national guideline in which a multidisciplinary task force utilized the modified...
4.
Al-Jedai A, Mayet A, Khurshid F, Alsultan M
Saudi Pharm J
. 2024 Jan;
32(2):101952.
PMID: 38283152
Purpose: Our study aims to provide an overview of medication therapy monitoring practices carried out by pharmacists in hospitals across the Gulf Cooperation Council (GCC) countries. Methods: This is a...
5.
Azzam N, AlMutairdi A, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, et al.
Saudi J Gastroenterol
. 2023 Dec;
PMID: 38099556
The management of inflammatory bowel disease (IBD) in pregnant women is challenging and must be addressed on a patient-by-patient basis. Optimal patient management requires a multidisciplinary team and clear evidence-based...
6.
Al Aseri Z, Algahtani F, Bakheet M, Al-Jedai A, Almubrik S
J Cardiovasc Pharmacol Ther
. 2023 Oct;
28:10742484231202655.
PMID: 37872658
The indications of direct oral anticoagulants (DOACs) have expanded over the past 15 years. DOACs are effective and safe oral anticoagulants associated with lower bleeding risks and mortality than vitamin...
7.
Mayet A, Khurshid F, Al-Omar H, Alghanem S, Alsultan M, Al-Jedai A
Saudi Pharm J
. 2023 Apr;
31(3):453-461.
PMID: 37026051
Purpose: To outline dispensing and administration practices in hospital pharmacy across the Gulf Cooperation Councils (GCC) countries' hospitals. Paucity of data in appraising hospital pharmacy practice in GCC regions motivated...
8.
Mosli M, Almudaiheem H, AlAmeel T, Bakkari S, Alharbi O, Alenzi K, et al.
Saudi J Gastroenterol
. 2022 Nov;
PMID: 36412460
Optimal management of inflammatory bowel disease (IBD) relies on a clear understanding and tailoring evidence-based interventions by clinicians in partnership with patients. This article provides concise guidelines for the management...
9.
Saudi consensus recommendations on the management of Neuromyelitis Optica Spectrum Disorders (NMOSD)
Shosha E, Aljarallah S, Al Fugham N, Al-Jedai A, Al Luqmani M, Al Malik Y, et al.
Mult Scler Relat Disord
. 2022 Jul;
66:104062.
PMID: 35908449
This article focuses on the diagnosis and management of neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune, demyelinating condition characterized by inflammation of the optic nerve and/or the spinal...
10.
Bunyan R, AlAbdulSalam A, Albarakati R, Al Harbi A, Alissa D, Al-Jedai A, et al.
Mult Scler Relat Disord
. 2022 Jul;
66:104061.
PMID: 35908447
Multiple sclerosis (MS) most commonly presents in young adults, although 3-5% of patients develop MS prior to the age of 18 years. The new and comprehensive consensus for the management...